AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Nonlinear Kerr effect === Under intense laser illumination, graphene exhibits a nonlinear phase shift due to the optical nonlinear Kerr effect. Graphene demonstrates a large nonlinear Kerr coefficient of 10−7 cm2⋅W−1, nearly nine orders of magnitude larger than that of bulk dielectrics, suggesting its potential as a powerful nonlinear Kerr medium capable of supporting various nonlinear effects, including solitons.
== History == APP was founded in 2007 and incorporated in February 2008 by laboratory professionals, Edward Dooling and Thanasis Papaioanu, along with hospital executive, Martin Rash. Edward Dooling was formerly a senior executive with AmeriPath (now part of Quest Diagnostics) and DIANON Systems, Inc., (now part of LabCorp). Thanasis Papaioanu was formerly an investment banker with SunTrust Equitable (now SunTrust Robinson Humphrey) and FTN Financial (part of First Tennessee National Corporation), where he helped launch New York-based laboratory CBLPath, Inc. (now part of Sonic Healthcare). Martin Rash is founder and Chairman/CEO of RegionalCare Hospital Partners; he was formerly founder and Chairman/CEO of publicly traded Province Healthcare Company that was acquired by Lifepoint Hospitals, Inc. (Nasdaq: LPNT) in 2005. In April 2008, APP secured a $75 million equity commitment from New Enterprise Associates (NEA), a large private equity investment firm based in Menlo Park, California and Baltimore, Maryland. On December 31, 2008, APP completed the acquisition of UniPath, LLC in Denver, Colorado. APP operates the technical operation while UniPath, P.C., the affiliated 25+ pathologist medical practice, stays independent and continues to be owned and managed by the pathologists. On March 12, 2009, the firm completed the acquisition of Eastern Carolina Pathology, Inc. in Wilson, North Carolina.
=== Design of membrane proteins === Several transmembrane proteins have been successfully designed, along with many other membrane-associated peptides and proteins. Recently, Costas Maranas and his coworkers developed an automated tool to redesign the pore size of Outer Membrane Porin Type-F (OmpF) from E.coli to any desired sub-nm size and assembled them in membranes to perform precise angstrom scale separation.
=== Vascular and metabolic disease expression === ITGA1 expression is also altered in non-cancer disease states. In diabetic foot ulcers (DFU), ITGA1 is upregulated in wound tissues from diabetic patients and in advanced glycation and end product (AGE)-treated human endothelial cells. Increased ITGA1 expression is associated with endothelial dysfunction, impaired proliferation and migration, reduced tube formation, and increased cellular senescence. Reduction of ITGA1 expression improves endothelial functional responses, suggesting that disease-associated ITGA1 activation contributes to impaired wound healing.
==== Acquired ==== Acquired Von Willebrand syndrome can occur due to autoantibodies, either interfering with platelet or collagen binding; increasing VWF clearance from the plasma; adsorption to myeloma cells or platelets; or proteolytic cleavage of VWF after shear stress-induced unfolding. A form of acquired VWD occurs in patients with aortic valve stenosis, leading to gastrointestinal bleeding (Heyde's syndrome). This form of acquired VWD may be more prevalent than is presently thought. In 2003, Vincentelli et al. noted that patients with acquired VWD and aortic stenosis who underwent valve replacement experienced a correction of their hemostatic abnormalities, but that the hemostatic abnormalities can recur after 6 months when the prosthetic valve is a poor match with the patient. Similarly, acquired VWD contributes to the bleeding tendency in people with an implant of a left ventricular assist device (a pump that pumps blood from the left ventricle of the heart into the aorta).
Sources: en.wikipedia.org
==== Literature ==== The fantasy novel Fourth Wing by Rebecca Yarros presents a main character, Violet Sorrengail, who has an unnamed chronic condition that aligns closely with EDS symptoms. When asked about this connection, Rebecca Yarros agrees with the connection but says EDS goes unnamed due to the level of medical knowledge present in her story's world. Yarros has EDS and included it as a representation of her condition.
=== Macrophages === One of the roles of macrophages is to phagocytize other expended phagocytes, bacteria and damaged tissue, and they also debride damaged tissue by releasing proteases. Macrophages function in regeneration and are essential for wound healing. They are stimulated by the low oxygen content of their surroundings to produce factors that induce and speed angiogenesis and they also stimulate cells that reepithelialize the wound, create granulation tissue, and lay down a new extracellular matrix. By secreting these factors, macrophages contribute to pushing the wound healing process into the next phase. They replace PMNs as the predominant cells in the wound by two days after injury. The spleen contains half the body's monocytes in reserve ready to be deployed to injured tissue. Attracted to the wound site by growth factors released by platelets and other cells, monocytes from the bloodstream enter the area through blood vessel walls. Numbers of monocytes in the wound peak one to one and a half days after the injury occurs. Once they are in the wound site, monocytes mature into macrophages. Macrophages also secrete a number of factors such as growth factors and other cytokines, especially during the third and fourth post-wounding days. These factors attract cells involved in the proliferation stage of healing to the area. In wound healing that result in incomplete repair, scar contraction occurs, bringing varying gradations of structural imperfections, deformities and problems with flexibility. Macrophages may restrain the contraction phase.
== Health == Type V Collagen studies show that Collagen V plays some other roles in different parts of the body. These roles can be both beneficial and harmful. Beneficial roles that Type V collagen plays in the body are:
Despite the anomalous electron configuration for gaseous thorium atoms, metallic thorium shows significant 5f involvement. A hypothetical metallic state of thorium that had the [Rn]6d27s2 configuration with the 5f orbitals above the Fermi level should be hexagonal close packed like the group 4 elements titanium, zirconium, and hafnium, and not face-centred cubic as it actually is. The actual crystal structure can only be explained when the 5f states are invoked, proving that thorium is metallurgically a true actinide. Tetravalent thorium compounds are usually colourless or yellow, like those of silver or lead, as the Th4+ ion has no 5f or 6d electrons. Thorium chemistry is therefore largely that of an electropositive metal forming a single diamagnetic ion with a stable noble-gas configuration, indicating a similarity between thorium and the main group elements of the s-block. Thorium and uranium are the most investigated of the radioactive elements because their radioactivity is low enough not to require special handling in the laboratory.
=== Evidence of mass incarceration === The focus of the administration's National Drug Strategy (NDS) called for tough guaranteed punishment for drug dealers and a reduced response in penalties for users. The plan also laid out funding for treatment and education but ultimately believed that "none of these can be effective unless America restores the rule of law in its cities and holds drug users accountable for the damage they cause society." The policy laid out by the administration represented the largest increase in resources for law enforcement in the nations history. Critics have stated that the policy spawned the creation of the prison–industrial complex. The NDS allocated nearly $1.5 billion in 1990 for the construction of 24,000 new federal prison beds, an increase of 1 billion dollars from 1989. The policy also increased funding for security in public housing projects from $8 million to $50 million. By the end of Bush's presidency in 1993, he had presided over one of the greatest hikes in imprisonment in the nation's history. During his four years, there was a 39% increase in incarcerations, an increase of 16,946 prisoners from the eight years of the Reagan administration. By the end the Bush presidency, 9.18% of all black people in the United States were in prison, on probation, or on parole, but only 1.76% of the white population in the United States were in one of those situations. In 1993, there were 6 times as many black Americans in local jails per 100,000 inmates as there were white Americans.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.